Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
70%(7 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
4
33%
Ph phase_1
1
8%
Ph phase_2
7
58%

Phase Distribution

1

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
7(58.3%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 27 (58.3%)
Phase 34 (33.3%)

Trials by Status

withdrawn18%
completed1083%
terminated18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03215758
completedphase_3

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03226392
terminatedphase_2

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

NCT03810183
completedphase_3

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02563067
completedphase_2

Dose Finding Study for QAW039 in Asthma

NCT01437735
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03215758Phase 3

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Completed
NCT03226392Phase 3

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Completed
NCT03810183Phase 2

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

Terminated
NCT02563067Phase 3

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Completed
NCT01437735Phase 2

Dose Finding Study for QAW039 in Asthma

Completed
NCT03087942Phase 1

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Completed
NCT02555683Phase 3

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Completed
NCT03989635Phase 2

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

Withdrawn
NCT01836471Phase 2

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Completed
NCT01804400Phase 2

A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber

Completed
NCT01785602Phase 2

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Completed
NCT01545726Phase 2

Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12